The global hematologic malignancies market size is expected to reach USD 120.56 Billion by 2028 at a CAGR of 10.7%, according to the latest report by Reports and Data. Rising prevalence of blood cancer, presence of strong pipeline therapeutics, and increasing expenditure in healthcare sector are key factors expected to drive market revenue growth over the forecast period. In addition, rapidly increasing geriatric population, rising awareness about early diagnosis and treatment, growing focus on developing advanced therapeutics, and increasing product approvals are expected to support market growth going ahead.

Hematologic malignancies are cancers that affect bone narrow, blood, and lymph nodes, and include different types of leukemia, myeloma, and lymphoma. Hematological malignancies account for nearly 9% of total newly diagnosed cancers in the United States. Blood cancer generally occur when there is rapid and uncontrollable growth of abnormal cells which interfere with development and functioning of normal cells. Hematologic malignancies are subdivided according to the type of blood cells that are affected. Lymphoblastic or lymphocytic malignancies occur in the lymphoid lineage, while myelogenous or myeloid malignancies occur in myeloid lineages. Treatment of hematologic malignancies is largely based on treating and alleviating symptoms. Aggressive hematologic malignancies require treatment with chemotherapy, immunotherapy, radiotherapy, and bone marrow transplant. increasing number of patients requiring chemotherapy and bone marrow transplant has increased over the recent past and this is expected to drive demand for these therapeutic approaches going ahead.

Over the last decade, numerous preclinical and clinical researches have generated encouraging results for treatment of hematological malignancies. Improved long-term outcomes for patients suffering from hematologic malignancies owing to rapid progress in therapeutics and drugs has contributed significantly to revenue growth of the market. Increasing funding and investment to accelerate cancer research is also expected to drive market growth. However, high costs of treatment and lack of skilled professionals is expected to restrain market growth to a certain extent over the forecast period.

To Gain Access to an all-inclusive PDF Sample Report, Click Here: https://www.reportsanddata.com/sample-enquiry-form/4056

Leading companies operating in the market and profiled in the report include:

Pfizer, Inc., F. Hoffmann-LA Roche ltd., Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company Limited.

Market Overview:

The pharmaceutical and healthcare sector is rapidly expanding in terms of revenue in the recent years and is expected to register robust CAGR over the forecast period of 2028. Factors such as rapid advancements in the pharma and healthcare sector, adoption of latest technologies, tools and equipment, emergence of various new diseases and improvements in healthcare facilities and infrastructure. In addition, rising healthcare expenditure, increasing per capita income in the developing countries and favorable reimbursement policies are fueling market growth. Increasing funds by various public and private sectors and increasing investments to develop enhanced products and devices are also boosting market growth. Moreover, increasing preference for ambulatory services and point of care services, and increasing funds for research centers and hospitals for drug discovery is expected to fuel market growth going ahead.

Competitive Landscape:

The report provides details about competitive landscape of global Hematologic Malignancies market focusing on every market player, its global position, revenue generation product portfolio, company overview, financial planning and business expansion plans. The global Hematologic Malignancies market is quite competitive and comprises various key players at global and regional levels. Key players are investing in research and development activities, and strategizing various plans such as mergers and acquisitions, partnerships, joint ventures, new product launches, to enhance their product base and strengthen their market position.

Grab Your Report at an Impressive Discount! Please Click Here: https://www.reportsanddata.com/discount-enquiry-form/4056

Some Key Highlights From the Report:

• Leukemia segment is expected to register robust revenue growth over the forecast period owing to increasing prevalence of leukemia across the globe, availability of advanced oncology drugs and therapeutics, and increasing collaborations in the market to boost development of advanced therapeutics for leukemia.
• Chemotherapy segment is expected to account for largest revenue share during the forecast period, attributable to increasing application of chemotherapy in treatment of blood cancer. Chemotherapy is generally the first line of treatment for blood cancer and often uses a combination of drugs depending on the type of cancer.
• North America is expected to account for largest revenue share between 2021 and 2028, attributable to rising prevalence of hematologic malignancies, establishment of robust healthcare facilities, availability of advanced cancer therapeutics, and robust presence of key market players in the region.
• In April 2021, Arch Oncology, Inc., which is a clinical-stage oncology firm engaged in discovery and development of anti-CD47 therapeutics, closed a Series C round of financing at USD 105 Million. The funding will be used to accelerate clinical progress of differentiated anti-CD47 candidate for treating patients with solid tumors and hematologic malignancies.

Download Summary @ https://www.reportsanddata.com/download-summary-form/4056

For the purpose of this report, Reports and Data has segmented the hematologic malignancies market based on type, therapy, and region:  

Type Outlook (Revenue, USD Billion; 2018-2028)

• Leukemia
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Lymphoma
• Multiple Myeloma
• Others

Therapy Outlook (Revenue, USD Billion; 2018-2028)

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

Regional Outlook:

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of APAC)
• Latin America (Brazil, Rest of LATAM)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/4056

Thank you for reading the research report. We also provide report customization as per client request. Kindly contact us to know more about this customization feature and our team will offer you with the best suited report.

Browse More Reports:

Insulin Pens Market  Share, Size and Growth, By Product (Traditional insulin Pens and smart insulin Pens), By Usage (Prefilled Insulin Pens, Smart Insulin Pen Caps, Reusable Insulin Pens), By End-User And Segment Forecasts To 2028

Alopecia Market  Share, Growth & Analysis, By Disease (Alopecia Areata, Androgenetic Alopecia), By Application (Homecare settings and Dermatology clinics), By Sales Distribution (Over the Counter (OTC) and prescription), By Gender (Male, Female) And Segment Forecasts, 2018-2028

Anthrax Vaccines Market  Share, Demand & Analysis, By Product Type (Cell-Free PA Vaccines and Live Vaccines), By Application (Human Use, Animal Use), By End-User, And Segment Forecasts, 2020-2028

Anesthesia CO2 Absorbent Market  By Product Type (Soda Lime, Medisorb, Dragersorb, Amsorb, Litholyme, And Others), By Type, By Form, End-User, And Segment Forecasts, 2017-2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com